Etrolizumab

Drug Profile

Etrolizumab

Alternative Names: Anti-beta 7 - Genentech; Monoclonal antibody beta7; PRO145223; RG 7413; rhuMAb Beta7; rhuMAb β7; RO 5490261

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator Genentech
  • Developer Genentech; Roche
  • Class Antiulcers; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Alpha4-beta7 integrin antagonists; Integrin alphaEbeta7 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Crohn's disease; Ulcerative colitis

Most Recent Events

  • 01 Dec 2016 Genentech initiates a phase I trial in Healthy volunteers in USA (SC) (NCT02996019)
  • 01 Aug 2016 Genentech completes a phase II trial in Ulcerative colitis in USA, Australia, Belgium, Canada, Czech Republic, Germany, Hungary, Israel, New Zealand, Spain and United Kingdom (NCT01461317)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Ulcerative-colitis in Belgium (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top